| Biomarker ID | 699 |
| PMID | 21820414 |
| Year | 2011 |
| Biomarker | KBP4; CRKL; PDHB, PRDX3; HYPK; MYL6;KHSRP; ENO1; ANXA5 ; RPLP0; OSTF1; CFL1; TXNDC12 ; PFDN5 ; HRNR; COPS8 ; |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Cell Lines |
| Subjects | Humans |
| Regulation | Upregulated (Atleast 2 fold): [KHSRP; ENO1; ANXA5 ; RPLP0; OSTF1; CFL1; TXNDC12 ; PFDN5 ; HRNR; COPS8;]Downregulated (Atleast 0.5 fold): [KBP4; CRKL; PDHB, PRDX3; HYPK; MYL6;] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | CD44+ Vs CD44- Cells |
| Type of Biomarker | Prognostic |
| Cohort | DU145 prostate cancer cell line was isolated into CD44+ or CD44- cells.CD44+ cells possessed stem cell characteristics and highly expressed genes known to be important in stem cell maintenance |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | two-dimensional gel electrophoresis and LC-MS/MS |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on human patient cohort |
| Technical Name | KBP4, CRKL, PDHB, PRDX3, HYPK, MYL6, KHSRP, ENO1, ANXA5, RPLP0, OSTF1, CFL1, TXNDC12, PFDN5, HRNR, COPS8 |